Related Experiment Videos

Improved efficacy of extended release oxybutynin in children with persistent daytime urinary incontinence converted

Kyle J Van Arendonk1, Matthew J Knudson, J Christopher Austin

  • 1Division of Pediatric Urology, Department of Urology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.

Urology
|October 31, 2006
PubMed

Insights

Switching children with persistent daytime urinary incontinence from regular oxybutynin (Ditropan) to extended-release oxybutynin (Ditropan XL) improved bladder capacity and reduced wetting frequency. Many patients experienced significant improvement after the medication change.

Area of Science:

  • Pediatric Urology
  • Pharmacology
  • Clinical Medicine

Background:

  • Persistent daytime urinary incontinence affects children's quality of life.
  • Oxybutynin is a common anticholinergic medication used to treat overactive bladder.
  • Transitioning between formulations may impact treatment efficacy and patient experience.

Purpose of the Study:

  • To evaluate the effectiveness of switching from regular oxybutynin (Ditropan) to extended-release oxybutynin (Ditropan XL) in pediatric patients with persistent daytime urinary incontinence.

Main Methods:

  • Retrospective review of 27 children with daytime wetting who switched from Ditropan to Ditropan XL.
  • Analysis included patient demographics, reasons for change, uroflowmetry, side effects, and medication dosage.
  • Paired t-test was used for statistical analysis (P <0.05).

Main Results:

  • 13 out of 27 patients showed improvement or resolution of incontinence by the first visit after switching to Ditropan XL.
  • Significant increases in mean voided volume (38% to 53%) and total bladder capacity (55% to 70%) were observed.
  • While some side effects resolved, new ones emerged in 7 patients; however, overall bladder function improved.

Conclusions:

  • Switching to extended-release oxybutynin (Ditropan XL) can decrease wetting frequency in children with persistent incontinence.
  • The transition to Ditropan XL led to increased voided volume and bladder capacity.
  • Ditropan XL represents a viable alternative for managing persistent daytime urinary incontinence in pediatric patients.
Abstract

Related Concept Videos

Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Modified-Release Drug Delivery Systems: Drug Release Characteristics01:22

Modified-Release Drug Delivery Systems: Drug Release Characteristics

Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
IV Infusion to Oral Dosing: Conversion Methods01:28

IV Infusion to Oral Dosing: Conversion Methods

The development of extended-release formulations has facilitated the transition from intravenous to oral medication, offering a more convenient and patient-friendly approach to drug administration. This transition, however, requires careful management to ensure that therapeutic drug levels are maintained, preserving efficacy and avoiding adverse effects. Understanding pharmacokinetic principles and dosage calculations is critical during this process.Pharmacokinetics of the...